Sept 19 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX
* Clinuvel provides update on Scenesse FDA filing
* Clinuvel pharmaceuticals says European post-marketing safety data to be submitted as part of new drug application, expected in december 2017
* Seeking approval from FDA to market Scenesse in us
* Has agreed with fda that safety data generated under european pass will form part of nda submission
* Safety profile of Scenesse has been positive to date and no safety concerns have been detected from European distribution thus far
* Obtained a positive FDA answer on acceptance of current safety data, as FDA issued a carcinogenicity waiver in 2017
* First full statistical analyses of european post authorisation data are due to be available in December 2017